Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience

Background There is much interest in confirming whether the efficacy of abiraterone acetate (AA) demonstrated within the trial setting is reproducible in routine clinical practice. We report the clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with AA in real-life clinical practice.